These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9700544)

  • 1. Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. Sentry Antimicrobial Surveillance Program.
    Jones ME; Jones RN; Sader H; Verhoef J; Acar J
    J Antimicrob Chemother; 1998 Jul; 42(1):119-21. PubMed ID: 9700544
    [No Abstract]   [Full Text] [Related]  

  • 2. Susceptibility of staphylococci to paldimycin, and emergence of resistance, in vitro.
    Chandrasekar PH; Sluchak JA
    J Antimicrob Chemother; 1989 Nov; 24(5):821-4. PubMed ID: 2600003
    [No Abstract]   [Full Text] [Related]  

  • 3. [Staphylococci and enterococci resistant to glycopeptides: the challenge of the year 2000?].
    Mainardi JL
    Pathol Biol (Paris); 1998 May; 46(5):289-90. PubMed ID: 9769886
    [No Abstract]   [Full Text] [Related]  

  • 4. [Staphylococci causing nosocomial infections in pediatric units. Sensitivity to glycopeptides and primary antibiotics].
    Fabre R; Cavallo JD
    Presse Med; 1996 Feb; 25(5):214. PubMed ID: 8729387
    [No Abstract]   [Full Text] [Related]  

  • 5. Susceptibility of Brazilian staphylococcal strains to glycopeptides evaluated by different testing methods.
    Ferreira Nunes AP; Martins Teixeira L; Reis Bastos CC; de Souza Fonseca L; Netto dos Santos KR
    Curr Microbiol; 2002 Jun; 44(6):385-90. PubMed ID: 12000986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06.
    Hope R; Livermore DM; Brick G; Lillie M; Reynolds R;
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii65-74. PubMed ID: 18819981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Prevalence of Heterogeneously Glycopeptide-Intermediate Coagulase-Negative Staphylococci in Sternal Wounds.
    Berglund B; Claesson C; Nilsson LE; Hanberger H
    Antimicrob Agents Chemother; 2016 Aug; 60(8):5097-8. PubMed ID: 27216070
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycopeptides in the treatment of staphylococcal infections.
    Daschner FD; Kropec A
    Eur J Clin Microbiol Infect Dis; 1995; 14 Suppl 1():S12-7. PubMed ID: 7729466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
    Lin G; Credito K; Ednie LM; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):770-2. PubMed ID: 15673763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin.
    Greenwood D; Bidgood K; Turner M
    J Antimicrob Chemother; 1987 Aug; 20(2):155-64. PubMed ID: 2959642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin.
    Watanakunakorn C
    J Antimicrob Chemother; 1988 Sep; 22(3):321-4. PubMed ID: 2972670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of gram positive cocci to teicoplanin. Three year survey (1984-1986) at Perugia University.
    Pasticci MB; Baldelli F; Moretti A; Menichetti F; Pauluzzi S
    Boll Ist Sieroter Milan; 1989; 68(1):5-6. PubMed ID: 2535245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial susceptibilities of oxacillin-resistant coagulase negative staphylococci.
    Flournoy DJ
    Methods Find Exp Clin Pharmacol; 1985 Jun; 7(6):333-5. PubMed ID: 3851133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Isolation of coagulase-negative teicoplanin-resistant staphylococci].
    Riegel P; Ellis A; Jehl F
    Presse Med; 1990 Jun; 19(22):1053. PubMed ID: 2141162
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance.
    Del Bene VE; John JF; Twitty JA; Lewis JW
    J Infect Dis; 1986 Aug; 154(2):349-52. PubMed ID: 2941491
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.
    Cercenado E; Cercenado S; Gómez JA; Bouza E
    J Antimicrob Chemother; 2003 Jul; 52(1):138-9. PubMed ID: 12805264
    [No Abstract]   [Full Text] [Related]  

  • 18. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998.
    Santos Sanches I; Mato R; de Lencastre H; Tomasz A;
    Microb Drug Resist; 2000; 6(3):199-211. PubMed ID: 11144420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
    Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci.
    Felmingham D; Solomonides K; O'Hare MD; Wilson AP; Grüneberg RN
    J Antimicrob Chemother; 1987 Oct; 20(4):609-10. PubMed ID: 2960645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.